Head-to-head evidence
Cemiplimab vs Sintilimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Cemiplimab
Marketed by Regeneron Pharmaceuticals and partners
NCT03088540 · Phase 3 · completed
This was a large, randomized, actively-controlled trial with two hard clinical endpoints, survival and progression-free survival, both of which showed a statistically significant benefit for cemiplimab (median overall survival 23.4 vs 13.7 months; progression-free survival assessed by an independent, blinded reviewer). However, patients and treating doctors knew which treatment was being given, since the study was not blinded, which is a real limitation despite the otherwise strong design and the clear-cut result.
Next expected readout: December 2026 · NCT06623656 (registry estimate)
Sintilimab
Developed by Innovent Biologics and partners
NCT03607539 · Phase 3 · completed
This trial was randomized, quadruple-blinded, and placebo-controlled with a reasonably large sample (397 patients) and used a hard clinical primary endpoint (progression-free survival), which is a strong design overall. However, the results record reports only median PFS values and confidence intervals for each arm (8.9 vs 5.0 months) without a p-value or hazard ratio, so whether the primary comparison reached statistical significance cannot be confirmed from the data provided.
Next expected readout: December 2026 · NCT06198907 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cemiplimab's landscape · Sintilimab's landscape